ChroMedX Receives US Patent on Flagship HemoPalm Analyzer Technology
TORONTO, ONTARIO -- (September 26, 2016) -
ChroMedX Corp. (CSE: CHX) (OTCQB: MNLIF) (Frankfurt: EIY2) (the "Company"), a developer of in vitro diagnostics and point of care testing (POCT) technologies is pleased to announce that it has received formal Notice of Allowance
from the United States Patent and Trademark Office (USPTO) for Pat. Application No. 15/144,073, which is a
continuation of PCT/CA2015/050455 filed 20th May 2015. The allowed patent is published under publication number US2016/0245793A1 titled “Joint Spectroscopic and Biosensor System for Point of Care Testing”, and can reviewed
through the link www.uspto.gov/patft/
The main patent claims cover the HemoPalm system, the HemoPalm cartridge, and a method for using the HemoPalm system. HemoPalm is positioned to be the only hand held POCT analyzer that combines Blood Gases & Electrolytes,
with full CO-oximetry. Currently this combination is only available in benchtop analyzers that are usually found in the
central laboratory. The significance of this patent is that patent protection of the HemoPalm system is now extended until 2035.
In June 2016, the Canadian version of the patent was allowed, and within the next 2 months, ChroMedX will be filing the same patent application in Europe, China, India, Japan and S. Korea. In 2014, the global market for Blood Gases & Electrolytes was estimated to be 1.5 Billion $US. The most popular POCT analyzer for measuring Blood Gases &
Electrolytes cannot provide COoximetry. These tests are essential for the Emergency Dept., Intensive Care Units, and use by first responders.
The HemoPalm system will also be able to use capillary blood from babies, and a separate or the same cartridge will
be able to measure bilirubin for detecting neonatal jaundice. A separate ChroMedX pending patent describes a
Capillary Adaptor for drawing capillary blood directly from the patient to the cartridge. Competitors must first collect
the blood in a separate tube, or collect arterial blood in a syringe. The collection of arterial blood is painful and puts
the patients at risks of for example, nerve damage. HemoPalm can use both arterial and capillary blood.
A complete list of the Company’s intellectual property can be found on the ChroMedX website at http://www.chromedx.com/intellectual-property/
About ChroMedX Corp.
ChroMedX Corp. is a medical technology company focused on the development of novel medical devices for in vitro diagnostics and point of care testing. The devices are protected by the Company’s issued US and pending international patents, dealing withblood collection, analysis and plasma/serum processing.
Follow ChroMedX Corp.:
o. 647-872-9982 ext. 2
TF. 1-844-247-6633 ext. 2
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
Forward-looking Information Cautionary Statement
Except for statements of historic fact, this news release contains certain "forward looking information" within the meaning of applicable securities law. Forward looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward looking statements are based on the opinions and estimates at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward looking statements including, but not limited to delays or uncertainties with regulatory approvals, including that of the CSE. There are uncertainties inherent in forward looking information, including factors beyond the Company’s control. The Company undertakes no obligation to update forward looking information if circumstances or management's estimates or opinions should change except as required by law. The reader is cautioned not to place undue reliance on forward looking statements. Additional information identifying risks and uncertainties that could affect financial results is contained in the Company’s filings with Canadian securities regulators, which filings are available at www.sedar.com